natgillin/translations-raw huggingface dataset:
Patienter, der modtager remissions-induktions kemoterapi for akut myeloid leukæmi (AML) eller myelodysplastiske syndromer (MDS), der forventes at resultere i langvarig neutropeni og som har høj risiko for at udvikle invasive svampeinfektioner;
Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;
Patienter, der modtager Temodal i kombination med strålebehandling kan opleve andre bivirkninger end patienter der kun får Temodal.
Patients receiving Temodal in combination with radiotherapy may experience different side effects than patients taking Temodal alone.
Patienter, der modtager Temodal i kombination med strålebehandling, kan opleve andre bivirkninger, end patienter der kun får Temodal.
Patients receiving Temodal in combination with radiotherapy may experience different side effects than patients using Temodal alone.
Patienter, der oplevede et svært flare (%)
Patients experiencing a severe flare (%)
Patienter, der oplever bivirkninger såsom maveproblemer, lysfølsomhedsreaktioner eller væsentlige ændringer i leverenzymniveauerne, skal måske have deres dosis reduceret, i det mindste midlertidigt.
Patients who experience side effects such as stomach problems, light-sensitive skin reactions or significant changes in the levels of liver enzymes may need to have their dose reduced at least temporarily.
Patienter, der oplever disse bivirkninger, må ikke føre motorkøretøj eller betjene maskiner.
Patients experiencing these adverse reactions should not drive or use machines.
Patienter, der oplever en signifikant reduktion af niveauet af frit kortisol i urinen [UFC], bør fortsat behandles med Signifor, så længe der opnås en gavnlig virkning.
Patients who experience a significant reduction in urinary free cortisol [UFC] levels should continue to receive Signifor for as long as benefit is derived.
Patienter, der oplever grad 1-neurologisk toksicitet
For patients experiencing grade 1-4 neurologic toxicity
Patienter, der oplever infusionsrelaterede reaktioner, bør informeres om ikke at føre motorkøretøj og betjene maskiner, før symptomerne er aftaget.
Patients experiencing infusion-related reactions should be advised not to drive and use machines until symptoms abate.
Patienter, der oplever ømme og smertende led, ledstivhed eller bevægelsesbesvær bør søge læge.
Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.
Patienter, der opnåede det tilsigtede trombocyttal og indledte antiviral behandlingc
Patients achieving target platelet counts & initiating antiviral therapy c
Patienter, der opnåede PASI-50 efter uge 32
Patients who achieved PASI-50 at Week 32
Patienter, der opnåede PASI-75 efter uge 32
Patients who achieved PASI-75 at Week 32
Patienter, der opnår en gavnlig effekt/patienter med abnormitet ved udgangsniveauet (%)
Patients with benefit/patients with abnormality at baseline (%)
Patienter, der opnår komplet respons, kan fortsætte behandlingen i mindst 2 cyklusser efter første tegn på komplet respons, også selv om dette kræver behandling i flere end 8 cyklus- ser.
Patients achieving a complete response can continue treatment for at least 2 cycles after the first evidence of complete response, even if this requires treatment for more than 8 cycles.
Patienter, der opnår respons eller stabiliseret sygdom efter 4 cyklusser med denne kombinationsbehand- ling, kan fortsætte med den samme kombination i højst 4 cyklusser yderligere.
Patients achieving a response or a stable disease after 4 cycles of this combination therapy can continue to receive the same combination for a maximum of 4 additional cycles.
Patienter, der opnår respons eller stabiliseret sygdom efter 4 cyklusser med denne kombinationsbehandling, kan fortsætte behandlingen med kombinationen i højst 4 yderligere cyklusser.
Patients achieving a response or a stable disease after 4 cycles of this combination therapy can continue to receive the same combination for a maximum of 4 additional cycles.
Patienter, der opnår respons eller stabiliseret sygdom efter 4 cyklusser med denne kombinationsbehandling, kan fortsætte behandlingen, med kombinationen i højst 4 yderligere cyklusser.
Patients achieving a response or a stable disease after 4 cycles of this combination therapy can continue to receive the same combination for a maximum of 4 additional cycles.
Patienter, der opretholdt  PASI 75-respons ved uge 33, og som oprindeligt var randomiseret til aktiv behandling i periode A, blev randomiseret igen i periode C til at få enten 40 mg Humira hver anden uge eller placebo i yderligere 19 uger.
Patients who maintained PASI 75 response at Week 33 and were originally randomised to active therapy in Period A, were re-randomised in period C to receive 40 mg Humira every other week or placebo for an additional 19 weeks.
Patienter, der opretholdt PASI 75-respons ved uge 33, og som oprindeligt var randomiseret til aktiv behandling i periode A, blev randomiseret igen i periode C til at få enten 40 mg Humira hver anden uge eller placebo i yderligere 19 uger.
Patients who maintained PASI 75 response at Week 33 and were originally randomised to active therapy in Period A, were re-randomised in period C to receive 40 mg Humira every other week or placebo for an additional 19 weeks.
Patienter, der oprindeligt var randomiseret til Taltz, og som responderede ved uge 12 (dvs. sPGA- score på 0,1) i UNCOVER-1 og UNCOVER-2, blev randomiseret på ny til yderligere 48 uger på et af følgende behandlingsregimer: placebo eller Taltz (80 mg hver 4. eller 12. uge [Q4W eller Q12W]).
Patients originally randomised to Taltz and who were responders at Week 12 (i.e., sPGA score of 0,1) in UNCOVER-1 and UNCOVER-2 were re-randomised to an additional 48 weeks of one of the following treatment regimens: placebo, or Taltz (80 mg every four or twelve weeks [Q4W or Q12W]).
Patienter, der overgår fra cysteaminbitartrat med hurtig udløsning til PROCYSBI, bør have kontrolleret leukocytternes cystinindhold inden for 2 uger og efterfølgende hver tredje måned for at vurdere, om dosis er optimal som ovenfor beskrevet.
Patients being transferred from immediate-release cysteamine bitartrate to PROCYSBI should have their WBC cystine levels measured in 2 weeks, and thereafter every 3 months to assess optimal dosage as described above.
Patienter, der overholder alle kriterierne for CR undtagen normalisering af trombocyttal til
Patients who met all of the criteria for a CR except for recovery of platelet counts to > 100 x 109/l
Patienter, der planlægger at blive gravide, bør skifte til anden antihypertensiv behandling hvor sikkerhedsprofilen for anvendelse under graviditet er veletableret, medmindre fortsat behandling med AIIRA'er skønnes nødvendig.
Unless continued AIIRAs therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy.
Patienter, der planlægger at blive gravide, bør skifte til anden antihypertensiv behandling, hvor sikkerhedsprofilen for anvendelse under graviditet er veletableret, medmindre fortsat behandling med AIIRA skønnes nødvendig.
Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative anti- hypertensive treatments which have an established safety profile for use in pregnancy.
Patienter, der planlægger at blive gravide, bør skifte til en alternativ antihypertensionsbehandling med en dokumenteret sikkerhedsprofil til brug under graviditet, medmindre behandling med angiotensin II-
Unless continued angiotensin II receptor antagonist therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy.
Patienter, der planlægger at blive gravide, bør skifte til en alternativ antihypertensionsbehandling med en dokumenteret sikkerhedsprofil til brug under graviditet, medmindre behandling med angiotensin II- receptorantagonister sker på tvingende indikation.
Unless continued angiotensin II receptor antagonist therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy.
Patienter, der planlægger at blive gravide, bør skiftes til anden antihypertensiv behandling, hvor sikkerhedsprofilen for anvendelse under graviditet er veletableret, med mindre fortsat behandling med AIIRA’ere skønnes nødvendig.
Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy.
Patienter, der planlægger at blive gravide, bør ændre til anden antihypertensiv behandling hvor sikkerhedsprofilen for anvendelse under graviditet er veletableret, medmindre fortsat behandling med AIIRAer skønnes nødvendig.
Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy.
Patienter, der potentielt kan blive gravide, skal anbefales at bruge effektiv prævention under behandlingen.
Patients of child-bearing potential should be advised to use effective contraception while on treatment.
Patienter, der påbegynder en kombination af Betmiga og digoxin, bør indledningsvis få ordineret den laveste dosis af digoxin.
For patients who are initiating a combination of Betmiga and digoxin, the lowest dose for digoxin should be prescribed initially.
Patienter, der rapporterede PAH under dasatinib-behandling, tog ofte andre lægemidler eller havde komorbiditet i tillæg til den underliggende malignitet.
Patients with PAH reported during dasatinib treatment were often taking concomitant medicinal products or had co-morbidities in addition to the underlying malignancy.
Patienter, der rapporterer om rygetrang, rygeophør og forstærkende virkning af rygning
Patient reported craving, withdrawal and reinforcing effects of smoking
Patienter, der responderede på 8/10 ugers akut behandling med Thymanax 25-50 mg en gang dagligt i et ublindet studie blev randomiseret til enten Thymanax 25-50 mg en gang dagligt eller placebo i yderligere 6 måneder.
Patients responding to 8/10-weeks of acute treatment with open-label Thymanax 25-50 mg once daily were randomised to either Thymanax 25-50 mg once daily or placebo for further 6-months.
Patienter, der responderer på behandling, kan fortsat modtage 1000 mg Gazyvaro en gang hver anden måned i to år, eller så længe de har gavn af det.
Patients who respond to treatment, may continue to receive 1,000 mg Gazyvaro once every two months for two years or as long as they benefit from it.
Patienter, der samtidig bruger substrater for CYP2B6- og CYP2C9-enzymer eller BCRP-transportere, skal monitoreres nøje for bivirkninger.
Patients concomitantly using substrates of CYP2B6 and CYP2C9 enzymes or BCRP transporters, should be carefully monitored for adverse drug reactions.
Patienter, der samtidig er inficeret med HCV/hiv og som modtager peginterferon alfa-2b/ribavirin behandling og cART kan have øget risiko for at udvikle hæmatologiske unormaliteter (som neutropeni, trombocytopeniog anæmi) sammenlignet med HCV mono-inficerede patienter.
HCV/HIV co-infected patients receiving peginterferon alfa-2b/ribavirin treatment and cART may be at increased risk to develop haematological abnormalities (as neutropenia, thrombocytopenia and anaemia) compared to HCV mono-infected patients.
Patienter, der samtidig er inficeret med HCV/HIV og som modtager peginterferon alfa-2b/ribavirin behandling og HAART, kan have øget risiko for at udvikle hæmatologiske unormaliteter (som neutropeni, trombocytopeni og anæmi) sammenlignet med HCV-monoinficerede patienter.
HCV/HIV co-infected patients receiving peginterferon alfa-2b/ribavirin treatment and HAART may be at increased risk to develop haematological abnormalities (as neutropenia, thrombocytopenia and anaemia) compared to HCV mono-infected patients.
Patienter, der samtidig er inficeret med HCV/hiv og som modtager peginterferon alfa-2b/ribavirin- behandling og cART, kan have øget risiko for at udvikle hæmatologiske unormaliteter (som neutropeni, trombocytopeni og anæmi) sammenlignet med HCV-monoinficerede patienter.
HCV/HIV co-infected patients receiving peginterferon alfa-2b/ribavirin treatment and cART maybe at increased risk to develop haematological abnormalities (as neutropenia, thrombocytopenia andanaemia) compared to HCV mono-infected patients.
Patienter, der samtidig er inficeret med hcv/hiv, og som får peginterferon alfa-2b/ribavirin- behandling og HAART, kan have øget risiko for at udvikle hæmatologiske anomalier (som neutropeni, trombocytopeni og anæmi) sammenlignet med hcv mono-inficerede patienter.
HCV/HIV co-infected patients receiving peginterferon alfa-2b/ribavirin treatment and HAART may be at increased risk to develop haematological abnormalities (as neutropenia, thrombocytopenia and anaemia) compared to HCV mono-infected patients.
Patienter, der samtidig er inficeret med hiv og får høj-aktiv anti-retroviral terapi (HAART), kan have øget risiko for at udvikle mælkesyreacidose.
Patients co-infected with HIV and receiving Highly Active Anti-Retroviral Therapy (HAART) may be at increased risk of developing lactic acidosis.
Patienter, der samtidig tager medicin, hvis eksponering er afhængig af BCRP, og som har et snævert terapeutisk indeks, bør monitoreres nøje for tegn på ændret tolerance for det samtidige medikament på grund af øget eksponering under behandling med Tagrisso (se pkt.
Patients taking concomitant medications with disposition dependent upon BCRP and with narrow therapeutic index should be closely monitored for signs of changed tolerability of the concomitant medication as a result of increased exposure whilst receiving TAGRISSO (see section 5.2).
Patienter, der samtidigt behandles med antikoagulantia (f.eks. warfarin; acenocoumarol) bør regelmæssigt have foretaget fuldstændig blodtælling (trombocyttal), koagulationsfaktor (PT/INR) og objektiv undersøgelse.
Patients receiving concomitant treatment with anticoagulants (e.g. warfarin, acenocoumarole) may be periodically monitored by complete blood counts (platelets), coagulation factors (PT/INR) and physical examination.
Patienter, der skal have foretaget koronararteriebypass-operation (CABG-operation)
Patients who are to undergo coronary artery bypass graft (CABG) surgery
Patienter, der skal have medicinsk behandling, kan fortsætte med infusion af 0,25 mg/kg legemsvægt/time, i op til 72 timer.
Patients who are to be medically managed may continue the infusion of 0.25 mg/kg/h for up to 72 hours.
Patienter, der skal opereres dagen efter injektionen, skal have 74 MBq af det technetium Tc 99m-mærkede præparat.
Patients scheduled for surgery on the day after injection will receive 74 MBq technetium Tc 99m labelled product.
Patienter, der skal opereres eller have foretaget andre invasive indgreb
Patients who are to undergo surgery or other invasive procedures
Patienter, der skal opereres samme dag som injektionen, skal have 18,5 MBq af det technetium Tc 99m- mærkede præparat.
Patients scheduled for surgery on the day of injection will receive 18.5 MBq technetium Tc 99m labelled product.
Patienter, der skiftede
Patients who switched
Patienter, der skifter fra exenatid opløsning til injektion (Byetta) til depotformulering af exenatid (Bydureon), kan opleve forbigående øgning i koncentrationen af blodglucose, hvilket generelt bedres inden for de første to uger efter opstart af behandlingen.
Patients switching from immediate-release (Byetta) to prolonged-release (Bydureon) exenatide, may experience transient elevations in blood glucose concentrations, which generally improve within the first two weeks after initiation of therapy.
Patienter, der skifter fra exenatid opløsning til injektion (Byetta) til depotformulering af exenatid (Bydureon), kan opleve forbigående øgning i koncentrationen af blodglucose, hvilket generelt bedres inden for de første to uger efter opstart af behandlingen.
Patients switching from immediate-release (Byetta) to prolonged-release exenatide may experience transient elevations in blood glucose concentrations, which generally improve within the first two weeks after initiation of therapy.
Patienter, der skifter fra separate dapagliflozintabletter (10 mg total daglig dosis) og metformintabletter til Ebymect bør modtage den samme daglige dosis dapagliflozin og metformin, der tages allerede, eller den nærmeste terapeutisk egnede dosis metformin.
Patients switching from separate tablets of dapagliflozin (10 mg total daily dose) and metformin to Ebymect should receive the same daily dose of dapagliflozin and metformin already being taken or the nearest therapeutically appropriate dose of metformin.
Patienter, der skifter fra separate dapagliflozintabletter (10 mg total daglig dosis) og metformintabletter til Xigduo bør modtage den samme daglige dosis dapagliflozin og metformin, der tages allerede, eller den nærmeste terapeutisk egnede dosis metformin.
Patients switching from separate tablets of dapagliflozin (10 mg total daily dose) and metformin to Xigduo should receive the same daily dose of dapagliflozin and metformin already being taken or the nearest therapeutically appropriate dose of metformin.
Patienter, der skifter fra separate saxagliptin- og metformintabletter, skal have de doser af saxagliptin og metformin, der tages allerede.
Patients switching from separate tablets of saxagliptin and metformin should receive the doses of saxagliptin and metformin already being taken.
Patienter, der skifter fra Viramune 200 mg tabletter til Viramune depottabletter
Patients switching from Viramune immediate-release to Viramune prolonged-release
Patienter, der skifter fra Viramune tabletter til Viramune depottabletter
Patients switching from Viramune immediate-release to Viramune prolonged-release
Patienter, der skifter til Actraphane fra en anden insulintype, skal muligvis have øget antallet af daglige injektioner eller ændret dosis i forhold til dosis af deres sædvanlige insulinpræparater.
Patients transferred to Actraphane from another type of insulin may require an increased number of daily injections or a change in dose from that used with their usual insulin medicinal products.
Patienter, der skifter til Mixtard fra en anden insulintype, skal muligvis have øget antallet af daglige injektioner eller ændret dosis i forhold til dosis af deres sædvanlige insulinpræparater.
Patients transferred to Mixtard from another type of insulin may require an increased number of daily injections or a change in dose from that used with their usual insulin medicinal products.
Patienter, der starter behandling med AVAGLIM, som hidtil har fået andet sulfonylurinstof end glimepirid, kan have forøget risiko for hypoglykæmi (se afsnit 4.4).
Patients changing to AVAGLIM from sulphonylurea therapies other than glimepiride may be at an increased risk of hypoglycaemia (see section 4.4).
Patienter, der tager
Patients using
Patienter, der tager 200 mg tabletter eller oral suspension, kan skifte til depottabletter uden en optrapningsperiode.
Patients who are already on immediate-release tablets or oral suspension can switch to prolonged- release tablets without lead-in period.
Patienter, der tager antiepileptika, bør konsultere en læge inden behandling med alli, da de bør monitoreres for mulige ændringer i krampeanfaldenes frekvens og intensitet.
Convulsions have been reported in patients treated concomitantly with orlistat and antiepileptic medicinal products e.g. valproate, lamotrigine, for which a causal relationship to an interaction cannot be excluded.
Patienter, der tager Brinavess må ikke få lægemidler kaldet ”klasse I- og III-antiarytmika” intravenøst i løbet af fire timer før eller efter deres infusion af Brinavess.
Patients on Brinavess must not be given medicines called ‘class I and III anti-arrhythmics’ intravenously during the four hours before or after their Brinavess infusion.
patienter, der tager et andet antiviralt lægemiddel ved navn telbivudin
patients taking another antiviral medicine called telbivudine;
Patienter, der tager ethinylestradiol-holdige lægemidler (dvs. de fleste kombinerede p-piller og p- ringe), skal skifte til en alternativ præventionsmetode (f.eks. prævention med progestin alene eller ikke-hormonelle metoder), inden de starter behandling med Exviera med ombitasvir/paritaprevir/ritonavir (se pkt.
Patients who are taking ethinylestradiol -containing medicinal products (i.e. most combined oral contraceptives or contraceptive vaginal rings) must switch to an alternative method of contraception (e.g., progestin only contraception or non-hormonal methods) prior to initiating Exviera with ombitasvir/paritaprevir/ritonavir therapy (see sections 4.3 and 4.5).
Patienter, der tager ethinylestradiol-holdige lægemidler (dvs. de fleste kombinerede p-piller og p-ringe), skal skifte til en alternativ præventionsmetode (f.eks. prævention med gestagen alene eller ikke- hormonelle metoder), inden de starter behandling med Viekirax og dasabuvir (se pkt.
Patients who are taking ethinylestradiol-containing medicinal products (i.e. most combined oral contraceptives or contraceptive vaginal rings) must switch to an alternative method of contraception (e.g., progestin only contraception or non-hormonal methods) prior to initiating Viekirax and dasabuvir therapy (see sections 4.3 and 4.5).
Patienter, der tager Ferriprox, eller deres plejere skal have udleveret et ”huskekort”, der minder patienten om, hvordan lægemidlet tages på en sikker måde.
Patients taking Ferriprox, or their carers, must be given a reminder card with information on how to take the medicine safely.
Patienter, der tager INCIVO to gange dagligt, skal informeres om, at hvis de glemmer at tage en dosis INCIVO, og det opdages inden for 6 timer efter det sædvanlige tidspunkt, skal den foreskrevne dosis INCIVO tages hurtigst muligt sammen med føde.
When administered twice daily (b.i.d.), in case a dose of INCIVO is missed within 6 hours of the time it is usually taken, patients should be instructed to take the prescribed dose of INCIVO with food as soon as possible.
Patienter, der tager metformin (et af de aktive stoffer i Efficib), har i meget sjældne tilfælde (kan berøre op til 1 ud af 10.000 behandlede) oplevet den alvorlige tilstand laktacidose (for meget mælkesyre i blodet).
Very rarely (may affect up to 1 in 10,000 people) patients taking metformin (one of the active substances of Efficib) have experienced a serious condition called lactic acidosis (too much lactic acid in your blood).
Patienter, der tager metformin (et af de aktive stoffer i Janumet), har i meget sjældne tilfælde (kan berøre op til 1 ud af 10.000 behandlede) oplevet den alvorlige tilstand laktacidose (for meget mælkesyre i blodet).
Very rarely (may affect up to 1 in 10,000 people) patients taking metformin (one of the active substances of Janumet) have experienced a serious condition called lactic acidosis (too much lactic acid in your blood).
Patienter, der tager metformin (et af de aktive stoffer i Ristfor), har i meget sjældne tilfælde (kan berøre op til 1 ud af 10.000 behandlede) oplevet den alvorlige tilstand laktacidose (for meget mælkesyre i blodet).
Very rarely (may affect up to 1 in 10,000 people) patients taking metformin (one of the active substances of Ristfor) have experienced a serious condition called lactic acidosis (too much lactic acid in your blood).
Patienter, der tager metformin (et af de aktive stoffer i Velmetia), har i meget sjældne tilfælde (kan berøre op til 1 ud af 10.000 behandlede) oplevet den alvorlige tilstand laktacidose (for meget mælkesyre i blodet).
Very rarely (may affect up to 1 in 10,000 people) patients taking metformin (one of the active substances of Velmetia) have experienced a serious condition called lactic acidosis (too much lactic acid in your blood).